ONCOLOGY LETTERS 9: 1451-1457, 2015
Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer LIN YANG1*, YI YANG2*, QIONG QIN1, AIPING ZHOU1, JIANJUN ZHAO1, JINWAN WANG1, CHANG SHU2, XINGHUA YUAN1 and SONGNIAN HU2 1
Chinese Academy of Medical Sciences, Cancer Institute and Hospital, Beijing 100021; Chinese Academy of Sciences, Beijing Institute of Genomics, Beijing 100101, P.R. China
2
Received April 13, 2014; Accepted December 3, 2014 DOI: 10.3892/ol.2014.2821 Abstract. Gastric cancer (GC) is the second leading cause of cancer‑related mortality worldwide. The usual treatment of GC consists of surgery with additional adjuvant chemotherapy. In the present study, the feasibility and safety of adjuvant S‑1 plus oxaliplatin (SOX) chemotherapy for patients with GC and the optimal dosage of S‑1 were determined. Eligible patients were randomly assigned to either arm A (30 cases) receiving 70 mg/m 2 S‑1 (in two seperate half doses) daily or arm B (30 cases) receiving 80 mg/m 2 S‑1 (in two seperate half doses) daily. The S-1 was administered twice daily for 14 days followed by a 7‑day rest period for the third week. A total of 130 mg/m 2 oxaliplatin was administered on day 1 every 3 weeks for each arm. The cumulative rates of the relative total administration dose of S‑1 at 100% in the 6th treatment course was 71.4% [95% confidence interval (CI), 56.5‑90.3%] in arm A, which was significantly higher than 21.4% (95% CI, 10.5‑43.6%) in arm B (P=0.001). The most common grade 3/4 toxicities were neutropenia (19.6%), thrombocytopenia (19.6%) and vomiting (16.1%). Grade 3/4 thrombocytopenia was observed in 7.1% of patients in arm A and in 32.1% of patients in arm B (P=0.019). With regard to the adverse events induced by S‑1 administration, the incidence of diarrhea (3.6 vs. 42.9%; P1,500/l; a platelet count of >100,000/l; a hemoglobin level of >90 g/l; a serum bilirubin level of less than the upper limit of normal (ULN); a normal creatinine level; an alanine transaminase and aspartate transaminase level of
Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer LIN YANG1*, YI YANG2*, QIONG QIN1, AIPING ZHOU1, JIANJUN ZHAO1, JINWAN WANG1, CHANG SHU2, XINGHUA YUAN1 and SONGNIAN HU2 1
Chinese Academy of Medical Sciences, Cancer Institute and Hospital, Beijing 100021; Chinese Academy of Sciences, Beijing Institute of Genomics, Beijing 100101, P.R. China
2
Received April 13, 2014; Accepted December 3, 2014 DOI: 10.3892/ol.2014.2821 Abstract. Gastric cancer (GC) is the second leading cause of cancer‑related mortality worldwide. The usual treatment of GC consists of surgery with additional adjuvant chemotherapy. In the present study, the feasibility and safety of adjuvant S‑1 plus oxaliplatin (SOX) chemotherapy for patients with GC and the optimal dosage of S‑1 were determined. Eligible patients were randomly assigned to either arm A (30 cases) receiving 70 mg/m 2 S‑1 (in two seperate half doses) daily or arm B (30 cases) receiving 80 mg/m 2 S‑1 (in two seperate half doses) daily. The S-1 was administered twice daily for 14 days followed by a 7‑day rest period for the third week. A total of 130 mg/m 2 oxaliplatin was administered on day 1 every 3 weeks for each arm. The cumulative rates of the relative total administration dose of S‑1 at 100% in the 6th treatment course was 71.4% [95% confidence interval (CI), 56.5‑90.3%] in arm A, which was significantly higher than 21.4% (95% CI, 10.5‑43.6%) in arm B (P=0.001). The most common grade 3/4 toxicities were neutropenia (19.6%), thrombocytopenia (19.6%) and vomiting (16.1%). Grade 3/4 thrombocytopenia was observed in 7.1% of patients in arm A and in 32.1% of patients in arm B (P=0.019). With regard to the adverse events induced by S‑1 administration, the incidence of diarrhea (3.6 vs. 42.9%; P1,500/l; a platelet count of >100,000/l; a hemoglobin level of >90 g/l; a serum bilirubin level of less than the upper limit of normal (ULN); a normal creatinine level; an alanine transaminase and aspartate transaminase level of
